NAS10026,946−5.25%S&P7,428−3.39%GOLD$4,132+1.46%BTC$75,633−5.94%VIX23.84+43.53%latest tape · as of 18:03 UTC
The Screen · Healthcare · Medical Distribution
YI111 Inc ADR
YI · NASDAQ · USD · Market cap $26M · 1,063 employees
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price3.00 USD
Fair value1.50Our model only; no analyst estimate to cross-check.
Ethical score70.0/100
Value readOvervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-11Read Markdown3.55-15.5% to today ✓Markup gives way to Markdown first Markdown read since July
2026-10-02Read Markup3.55-15.5% to today Distribution gives way to Markup with volume flow in agreement
2026-08-18Read Distribution3.61-16.9% to today ✓Markdown gives way to Distribution after a 26% slide in 7 weeks
2026-07-02Read Markdown4.89-38.7% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
111 Inc ADR holds its Markdown at $3.00. Elevated stress, defensive posture warranted, held for 66 days.
As held on the ledger · 2026-11-04
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 66 days
Price at the screen
$3.00
Valuation
0.29 trailing · 21.43 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.67
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
10.76%
Below 33%
Interest-bearing debt is just 10.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
2.27%
Below 33%
Cash held in interest-bearing accounts and securities is 2.3% of assets, under the one-third limit.
Pass
Receivables
35.03%
Below 49%
Money owed to the company is 35.0% of assets, under the 49% limit.
Pass
Revenue purity
0.03%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
111 clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 11%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when YI's ethical verdict changes
Today YI passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our model only; no analyst estimate to cross-check.
Our analysis reads Overvalued vs our fair value, as of 4 Nov 2026: it trades above our $1.50 fair value estimate, none competitive moat.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 100.0% above the base estimate.
Where our models see it going: fair-value estimate $1.50, with a range of $1.50 to $1.82, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 21.4x forward earnings, the price already runs ahead of the business. It trades 100% above our $1.50 fair value, so you would be buying at a premium, not a discount. The none moat is real, but quality alone does not make an expensive price cheap.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to China and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
YI trades on NASDAQ (the company is based in China). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-27Markdown$3.00-15.5%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 37%.
2026-10-11Markdown · changed$3.55+0.0%Entry 7
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 37%.
2026-10-02Markup · changed$3.55+6.6%Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 37%.
2026-09-18Distribution$3.33-7.8%Entry 5
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 37%.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 26.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 37%.
2026-07-18Markdown$4.89+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 37%.
2026-07-03Markdown$4.89+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$4.89Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.